Stratasys Ltd.

Stratasys Ltd. Earnings Recaps

SSYS Information Technology 2 recaps
Next earnings: November 12, 2026 (estimated) · full calendar
Q2 2026 Aug 15, 2026

Stratasys shares edged up modestly (+1.8%) after reporting generally stable results, driven by sustained growth in consumables and aerospace & defense segments, though the market appeared cautious on broader outlook or margin expansion.

Key takeaways
  • Total revenue rose 3.7% sequentially, supported by record consumables sales that reflect high system utilization.
  • Aerospace & Defense remains the largest business unit, growing 17% year-over-year, fueled by expanding U.S. Air Force adoption and ongoing multi-system orders for flightworthy production parts.
  • Stratasys Direct parts manufacturing grew 12.1% year-over-year, with demand driven by defense-related drone production and munitions applications.
  • The company continues to focus on operational discipline and cost management, though no concrete margin improvement details were highlighted.
  • Pending acquisition of MarkForged aims to enhance production capabilities, particularly in aerospace and industrial verticals, signaling strategic expansion but not yet reflected in results.
Q3 2025 Nov 13, 2025

Stratasys Ltd. reported solid operating cash flow and earnings per share in Q3 2025, showcasing the resilience of its business model amidst macroeconomic challenges. Continued focus on operational excellence and customer engagement drives growth in high-value verticals, particularly in aerospace, defense, and medical devices.

Key takeaways
  • Strong year-over-year increase in hardware sales, with notable gains in aerospace and defense sectors, including purchases from Boeing and Honeywell.
  • Successful demonstration of advanced manufacturing capabilities during the U.S. Navy’s Trident Warrior 25 exercise, highlighting operational resilience and logistics efficiency.
  • Strategic adoption of the H350 platform by a major pharmaceutical company signals potential growth in medical device and drug development applications.
  • Expansion of customer partnerships in high-tech sectors, including a significant investment by a leading U.S. technology firm in Stratasys' F3300 systems for prototyping and production.
  • The commitment to sustainability and localized manufacturing remains central to the company’s long-term growth strategy, aligning with industry trends.